Healthcare / BiotechnologyNYSE American
$19.47
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
4/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$35M
P/E
N/A
•EV/EBITDA
N/A
•ROE
362.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $0.0 · net income $-17.3M · FCF $-21.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $0.00 | $0.00 | $4.5M | $4.9M | $1.5M | $-188597.00 | $117989.00 | $60.3M | $67.1M | $67.1M | $0.00 | — | — | $10361.00 | $73736.00 | $1.5M | $14.2M |
| Net Income | $-17.3M | $-17.3M | $-29.7M | $-24.0M | $-36.2M | $-33.6M | $-22.4M | $35.8M | $24.7M | $24.7M | $-51.7M | $-17.7M | $-13.9M | $-20.9M | $-17.3M | $-12.8M | $-1.8M |
| EBITDA | $-17.2M | $-17.2M | $-22.2M | $-32.2M | $-36.5M | $-33.3M | $-23.5M | $35.8M | $26.0M | $26.0M | $-49.2M | $-17.2M | $-15.7M | $-15.5M | $-17.8M | $-12.5M | $-1.7M |
| EPS | -32.15 | -32.15 | -101.16 | -2.21 | — | — | -0.10 | 0.16 | 0.12 | 0.12 | -0.33 | -0.15 | -0.13 | -0.21 | -0.49 | -0.64 | -0.18 |
| Operating Margin | — | — | -501.0% | -668.7% | -2491.6% | 17701.3% | -20007.6% | 59.3% | 38.6% | 38.6% | — | — | — | -150421.4% | -25476.5% | -925.4% | -21.3% |
| Net Margin | — | — | -662.3% | -495.2% | -2465.1% | 17813.9% | -19006.9% | 59.3% | 36.8% | 36.8% | — | — | — | -201352.9% | -23398.6% | -868.6% | -12.6% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | 0.00 | 0.01 | -1.22 | -0.80 | 0.80 | 0.00 | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-21.3M | $-21.3M | $-31.5M | $-29.7M | $-30.2M | $-99360.00 | $41.3M | $-21.8M | $1.7M | $12.7M | $-47.4M | $-13.4M | $-12.2M | $-13.7M | $-15.5M | — | $-5.7M |
| Returns | |||||||||||||||||
| ROE | 362.3% | 362.3% | 26669.9% | 1214.1% | -222.5% | -67.7% | -28.0% | 35.6% | 91.6% | -478.3% | 294.1% | -144.7% | -142.3% | -90.8% | -942.3% | -70.4% | -19.2% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | -100.0% | -100.0% | -7.5% | 230.5% | 878.6% | -259.8% | -99.8% | -10.2% | 0.0% | — | — | — | — | -85.9% | -95.0% | -89.6% | — |
| EPS Growth | 68.2% | 68.2% | -4477.4% | — | — | — | -162.5% | 33.3% | 0.0% | 136.4% | -120.0% | -15.4% | 38.1% | 57.1% | 23.4% | -255.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.